There is
Marchioli R, Kutti J, et al
Hydroxyurea is primarily given to prevent life-threatening complications of polycythemia vera such as blood clots
It is usually
Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera
In polycythemia vera, thromboembolic events are the most lethal complications and unfortunately often the initial manifestation of the disease
Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications
Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for patients with ET and PV at high risk for vascular complications
to reduce the red blood cell count and low-dose aspirin to prevent blood clots
Too many red blood cells can make your blood thick and sluggish and increase your risk of and complications such as
Brittany Cote
Efficacy and safety of low-dose
The V617F mutation of the Janus kinase 2 (JAK2) gene on the 9 th chromosome is found in 95%-97% of PV
2017;92:1131-1136
0 x 109/L ** May increase dose 8 weeks after initiation, and then at intervals of 2 weeks or longer
Polycythemia vera is an uncommon feline disease, and clinical reports on the use of hydroxyurea to manage the condition in the cat are lacking
capsule
Hydroxyurea is used to treat cancer of the white blood cells called chronic myeloid leukemia (CML)
It is usually well tolerated and cheap and has been proven effective in many studies for the prevention of thrombohemorrhagic complications associated with the
Background Hydroxyurea (HU) is among the most commonly used cytoreductive treatments for polycythemia vera (PV), but previous research and clinical experience suggest that not all patients respond optimally, consistently, or durably to HU treatment